XEOMIN® Safety | Pediatric Patients With Chronic Sialorrhea

XEOMIN is the First and Only FDA-Approved Neuromodulator For Pediatric Patients With Chronic Sialorrhea

Demonstrated Safety in Pediatric Patients With Chronic Sialorrhea1

Adverse Reactions Pinch to zoom
  • Safe and well tolerated, no new or unexpected safety concerns, low rate of dental caries AE
  • No increase of AE incidence with repeated dosing
  • The most frequently reported adverse reaction in patients ages 2–5 years after XEOMIN injections was nasopharyngitis (6%)1

Reference

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2020.